# Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

> **NCT03298412** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 10 (actual)

## Conditions studied

- High-risk Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT03298412
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-23
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Early Closure due to rare patient population
- **Last updated:** 2020-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298412, "Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03298412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*